ArticleScientific reports2025

Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2- advanced or metastatic breast cancer in China.

Caifeng Jia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.